跳转至内容
Merck
CN

RAB0223

Human IFN γ ELISA Kit

for cell and tissue lysates

登录 查看组织和合同定价。

选择尺寸


关于此项目

NACRES:
NA.77
UNSPSC Code:
41116158
Gene information:
human ... IFNG(3458)
Input:
sample type tissue lysate
sample type cell lysate
Species reactivity:
human
Storage temp.:
−20°C
Shipped in:
wet ice
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

Human IFN γ ELISA Kit, for cell and tissue lysates

species reactivity

human

packaging

kit of 96 wells (12 strips x 8 wells)

technique(s)

ELISA: suitable
capture ELISA: suitable

input

sample type tissue lysate
sample type cell lysate

assay range

inter-assay cv: <12%
intra-assay cv: <10%
sensitivity: 15 pg/mL
standard curve range: 20.6-15000 pg/mL

detection method

colorimetric

shipped in

wet ice

storage temp.

−20°C

Gene Information

human ... IFNG(3458)

Application

For research use only. Not for use in diagnostic procedures.
Please refer to the attached General ELISA KIT Procedure (sandwich, competitive & Indirect ELISA)
Human IFNγ ELISA Kit has been used in ELISA assay.

Biochem/physiol Actions

IFNG (interferon-γ) is a type-2 interferon, which is produced by Th (T helper cells)-1 lymphocytes, CD8 cytotoxic lymphocytes, natural killer (NK) cells, and natural killer T (NKT) cells. It plays an important role in innate and adaptive immune responses, and helps in defense against bacterial infections, dimorphic yeast and some viral infections. High expression of IFNG is common in many autoimmune diseases, such as systemic lupus erythematosis, Sjögren syndrome, inflammatory bowel disease and multiple sclerosis.

General description

The Human IFN-γ ELISA (Enzyme-Linked Immunosorbent Assay) kit is an in vitro enzyme-linked immunosorbent assay for the quantitative measurement of human IFN-γ cell lysate and tissue lysate.

Immunogen

Recombinant Human IFN-γ

Other Notes

A sample Certificate of Analysis is available for this product.
Please type the word sample in the text box provided for lot number.

试剂盒组分也可单独购买

产品编号
说明
化学品安全说明书

  • RABDIL6ELISA 5X Sample Diluent Buffer (Item D2)化学品安全说明书

  • RABELADEELISA 5X Assay/Sample Diluent Buffer E (Item E2)化学品安全说明书

  • RABLYSIS12X Cell Lysis Buffer (Item J)化学品安全说明书

  • RABSTOP3ELISA Stop Solution (Item I)化学品安全说明书

  • RABTMB3ELISA Colorimetric TMB Reagent (HRP Substrate, Item H)化学品安全说明书

  • RABWASH420X Wash Buffer (Item B)化学品安全说明书

pictograms

Corrosion

signalword

Warning

hcodes

Hazard Classifications

Met. Corr. 1

存储类别

8B - Non-combustible corrosive hazardous materials

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Association between B7-H1 and cervical cancer: B7-H1 impairs the immune response in human cervical cancer cells.
Tao J
Experimental and Therapeutic Medicine, 14(5), 4125-4133 (2017)
Benjamin J Murdock et al.
Journal of immunology (Baltimore, Md. : 1950), 193(8), 4107-4116 (2014-09-17)
The potent immunoregulatory properties of IL-10 can counteract protective immune responses and, thereby, promote persistent infections, as evidenced by studies of cryptococcal lung infection in IL-10-deficient mice. To further investigate how IL-10 impairs fungal clearance, the current study used an
Samuel T Haile et al.
Cancer immunology research, 2(7), 610-615 (2014-05-14)
Tumor cells use various methods of immunosuppression to overcome antitumor immunity. One such method is that of programmed death ligand-1 (PD-L1 or B7-H1), which upon binding its receptor PD-1 on T cells triggers apoptotic death of the activated T cells.
Yong-Chen Lu et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 20(13), 3401-3410 (2014-07-06)
Cancer immunotherapy with adoptive transfer of tumor-infiltrating lymphocytes (TIL) represents an effective treatment for patients with metastatic melanoma, with the objective regressions in up to 72% of patients in three clinical trials. However, the antigen targets recognized by these effective
Shigeo Koido et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 20(16), 4228-4239 (2014-07-25)
We performed a phase I trial to investigate the safety, clinical responses, and Wilms' tumor 1 (WT1)-specific immune responses following treatment with dendritic cells (DC) pulsed with a mixture of three types of WT1 peptides, including both MHC class I

相关内容

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持